Drugs / Honokiol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06566443 | Feb 2025 → Aug 2026 overdue | non-small cell lung carcinoma | The Methodist Hospital Research Institute | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06775314 Comparator | Mar → May 2025 overdue | acne | Indonesia University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Honokiol | “spot cream consist of Triethyl citrate, Ethyl linoleate, GT peptide-10, Honokiol, will be given to subjects to be applied every morning and evening in group 2” NCT06775314 ↗ |
| Modality | Small molecule | — CHEMBL16901 ↗ |
| Route | Oral | “given orally” NCT06566443 ↗ |